Valuation
- Market cap
- 6,000
- Revenue TTM
- $0
- Net income TTM
- $-2,660,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 200
- Avg volume
- 8,498
- Day's range
- $0.00 – $0.00
- Shares out
- 61,652,000
- Stochastic %K
- 0%
- Beta
- 2.05
- Analysts
- —
- Price target
- —
Company profile
NovAccess Global Inc., a biopharmaceutical company, engages in the development of novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 213 642 9268
- Website
- https://www.novaccessglobal.com
- Address
- 459 Columbus Ave, Suite 607, New York, United States
Latest news
No headlines yet.
